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Roles of macrophages in measles virus infection of genetically
modified mice
Abstract
Knowledge of the mechanisms of virus dissemination in acute measles is cursory, but cells of the
monocyte/macrophage (MM) lineage appear to be early targets. We characterized the dissemination of
the Edmonston B vaccine strain of measles virus (MV-Ed) in peripheral blood mononuclear cells
(PBMC) of two mouse strains expressing the human MV-Ed receptor CD46 with human-like tissue
specificity and efficiency. In one strain the alpha/beta interferon receptor is defective, allowing for
efficient MV-Ed systemic spread. In both mouse strains the PBMC most efficiently infected were
F4/80-positive MMs, regardless of the inoculation route used. Circulating B lymphocytes and
CD4-positive T lymphocytes were infected at lower levels, but no infected CD8-positive T lymphocytes
were detected. To elucidate the roles of MMs in infection, we depleted these cells by clodronate
liposome treatment in vivo. MV-Ed infection of splenic MM-depleted mice caused strong activation and
infection of splenic dendritic cells (DC), followed by enhanced virus replication in the spleen. Similarly,
depletion of lung macrophages resulted in strong activation and infection of lung DC. Thus, in MV
infections of genetically modified mice, blood monocytes and tissue macrophages provide functions
beneficial for both the virus and the host: they support virus replication early after infection, but they
also contribute to protecting other immune cells from infection. Human MM may have similar roles in
acute measles.
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Knowledge of the mechanisms of virus dissemination in acute measles is cursory, but cells of the monocyte/
macrophage (MM) lineage appear to be early targets. We characterized the dissemination of the Edmonston
B vaccine strain of measles virus (MV-Ed) in peripheral blood mononuclear cells (PBMC) of two mouse strains
expressing the human MV-Ed receptor CD46 with human-like tissue specificity and efficiency. In one strain the
alpha/beta interferon receptor is defective, allowing for efficient MV-Ed systemic spread. In both mouse strains
the PBMC most efficiently infected were F4/80-positive MMs, regardless of the inoculation route used.
Circulating B lymphocytes and CD4-positive T lymphocytes were infected at lower levels, but no infected
CD8-positive T lymphocytes were detected. To elucidate the roles of MMs in infection, we depleted these cells
by clodronate liposome treatment in vivo. MV-Ed infection of splenic MM-depleted mice caused strong
activation and infection of splenic dendritic cells (DC), followed by enhanced virus replication in the spleen.
Similarly, depletion of lung macrophages resulted in strong activation and infection of lung DC. Thus, in MV
infections of genetically modified mice, blood monocytes and tissue macrophages provide functions beneficial
for both the virus and the host: they support virus replication early after infection, but they also contribute to
protecting other immune cells from infection. Human MM may have similar roles in acute measles.
Measles virus (MV) causes a highly contagious disease that
is a major cause of childhood morbidity and mortality in de-
veloping countries. After person-to-person transmission by the
respiratory route, the virus spreads from the upper respiratory
tract mucosa and lungs to lymphoid tissues, where replication
occurs primarily in macrophage- and lymphoid-multinucleated
giant cells (37, 38, 43). MV also spreads to numerous other
organs, and in these the virus replicates in endothelial and
epithelial cells (26). The rash occurring about 2 weeks after
infection marks the onset of a strong immune response which
is effective in clearing virus and establishing long-term immu-
nity (13). However, at this time numerous abnormalities of
immune responses are also detected, which contribute to mea-
sles morbidity and mortality (5). This immune suppression is
milder after vaccination with the live attenuated strain Edmon-
ston B (MV-Ed).
Characterization of the first steps in systemic MV dissemi-
nation is a priority because it may give insights into mecha-
nisms of MV pathogenesis, including immune suppression.
Since humans are the only natural MV host, and human tissues
can rarely be obtained immediately after contagion, knowledge
of the first steps in systemic MV dissemination is at best cur-
sory. Nevertheless, MV infection has been detected in several
types of human peripheral blood mononuclear cells (PBMC),
including monocytes (8, 17, 20), but also T and B lymphocytes
(29). Moreover, dendritic cells (DC) can be infected in vitro
(11, 14, 34). In cases where the virus disseminates in the central
nervous system (13), CD68-positive hematogenous macro-
phages/microglia cells are infected (25).
In the absence of a small-animal model that mimics human
disease, information about the initial steps of MV dissemina-
tion has been initially sought in primates. Experimentally in-
fected monkeys develop a disease similar to that of humans
(24), and PBMC become positive for MV as early as 2 days
postinfection (p.i.), with a peak on day 7 (1, 32, 45). Histolog-
ical examinations of monkey lymphoid tissues revealed prom-
inent infection of both macrophage- and lymphoid-multinucle-
ated giant cells (15, 24, 36) similar to those found in humans.
Ethical considerations and the fact that primates are costly
and in short supply have driven the development of rodent
models for MV infection. Genetically modified mice express-
ing a human MV receptor have recently been produced with
the intent of establishing a practical animal model of measles.
In particular, mice expressing the ubiquitous regulator of com-
plement activation CD46, one of the MV receptors (7, 30, 39)
with human-like tissue specificity, were developed (4, 28, 44).
Notwithstanding that in two of these mouse strains lung MV
replication was below (4) or only slightly above (28) the detec-
tion level, in a third mouse strain MV replication in PBMC and
lymphoid tissues was clearly documented (31). These MV in-
fection-permissive mice express CD46 at levels higher than
those in humans (21), possibly because they have multiple
integrated copies of the CD46 gene (44). Moreover, after
crossing one of these mouse strains in an alpha/beta interferon
receptor knockout background, efficient MV replication in
lungs and lymphatic organs was documented (27, 28). Based on
the observation that in infected organs virus replication was
* Corresponding author. Mailing address: Molecular Medicine Pro-
gram, Mayo Clinic, Guggenheim 18, 200 First St. SW, Rochester, MN
55905. Phone: (507) 284 0171. Fax: (507) 266 2122. E-mail: cattaneo
.roberto@mayo.edu.
3343
often monitored in F4/80-positive cells, macrophages were
identified as potential vectors for MV dissemination in mice
(27). Consistent with this observation, monocytes/macrophages
(MM), which serve generally as a first-line defense in the in-
nate immune system against pathogens (9), appear to be prime
target cells for MV during acute infection in humans (8).
In this study, we aimed at characterizing the host cells rep-
licating MV immediately after infection. We used our two
mouse strains expressing CD46 with human-like tissue speci-
ficity and efficiency, one (CD46Ge) with a functional alpha/
beta interferon receptor, the other (Ifnarko-CD46Ge) lacking
this receptor. The levels of infection of different classes of
PBMC were quantified; F4/80-positive (F4/801) MM were in-
fected with the highest efficiency in both mouse strains. Sys-
temic MV spread was then monitored in Ifnarko-CD46Ge
mice. When MM were depleted by clodronate liposomes treat-
ment in vivo, numerous infected DC were detected in the
spleen and lungs, and splenic virus replication was increased.
MATERIALS AND METHODS
Animals and infections. The two genetically modified mouse lines, CD46Ge,
expressing a human CD46 gene with human-like tissue specificity, and Ifnarko-
CD46Ge, with in addition a defective (knockout insertion) alpha/beta interferon
receptor gene, have been described previously (28).
Animals were bred under specific-pathogen-free conditions and infected at 5
to 8 weeks of age. Infection of anesthetized mice was performed intranasally
(i.n.) with 106 PFU of MV-Ed in 50 ml, intraperitoneally (i.p.) in 200 ml, or
intracerebrally (i.c.) in 30 ml. Noninfected or mock-infected mice inoculated with
the postnuclear fraction of uninfected Vero cells served as controls.
Viruses. Tagged MV-Ed vaccine virus was used (33). All virus stocks were
propagated in Vero cells and quantified by standard plaque assay on Vero cells.
Flow cytometric analysis on PBMC. Blood samples were collected from in-
fected animals, and PBMC were isolated by gradient centrifugation on Ficoll-
Paque (Pharmacia, Uppsala, Sweden) for 30 min at 400 3 g. Isolated mouse
PBMC were washed three times with phosphate-buffered saline (PBS) contain-
ing 2% fetal calf serum (FCS) and then resuspended at a density of 106 cells/200
ml. A double-staining assay, i.e., MV versus cell type-specific staining, was per-
formed by incubating PBMC with biotinylated anti-MV H monoclonal antibody
clone 55 (1:100) (kindly provided by Branka Horvat and Fabian Wild, Lyon,
France) and appropriate cell-specific antibodies (1 mg per million cells) for 60
min on ice. The following cell-specific rat anti-mouse antibodies were used: for
identification of CD4 T cells, fluorescein isothiocyanate (FITC)-conjugated anti-
CD4; for CD8 T cells, anti-CD8–FITC; for B cells, anti-CD45R/B220–FITC; and
for F4/80 MM, anti F4/80–FITC. All antibodies were from Serotec, United
Kingdom. After three washes with PBS containing 2% FCS, samples were incu-
bated for a further 45 min with a streptavidin-phycoerythrin conjugate for label-
ing of biotinylated primary anti-MV antibodies (PharMingen, San Diego, Calif.)
When Fc receptor-expressing cell populations (B lymphocytes or MM) were
analyzed, the samples were preincubated with Fc Block (PharMingen) for 15 min
on ice in order to reduce Fc receptor-mediated binding. The samples from
noninfected mice served as negative controls, and MV-infected Vero cells served
as a positive control. Flow cytometry analyses were carried out on a FACScan
instrument (Becton Dickinson). A live gate based on forward and side scatter
was used to exclude dead cells and doublets; at least 20,000 events were collected
for T or B cells, and at least 10,000 events were collected for MM. A fixed
window was set on the positive cell-specific population in order to count the
number of MV-positive specific cells in PBMC bulk culture. Statistical analysis
was done with CricketGraph 3.0 software after background correction, and
means of numbers and percentages of double-stained positive cells are pre-
sented. It is of note that MV-induced syncytia are large size and have poor
viability, and thus only MV-infected single cells could be analyzed with this
method.
CD46 was detected on the surface of PBMC by incubation with anti-CD46
monoclonal antibody clone 11/88 (1:50, vol/vol) and labeling with goat anti-
mouse immunoglobulin G1–R-phycoerythrin conjugate (Southern Biotechnol-
ogy Associates, Birmingham, Ala.).
Reisolation of MV from PBMC. Heparinized blood specimens were collected
from infected mice on day 3 p.i., and PBMC were isolated as described above and
washed five times with PBS containing 10% FCS and twice with Dulbecco’s
modified Eagle’s medium supplemented with 10% FCS. Fractionation of cell
populations was done by adherence to plastic in a 12-well tissue culture plate
(Becton Dickinson) for 3 h at 37°C. After adsorption, the nonadherent cells were
transferred to a new 12-well tissue culture plate at a density of 106 cells/ml, and
the culture medium was supplemented with 10 U of mouse interleukin-2 (Sigma)
per ml and 10 mg of lipopolysaccharide (LPS) (Sigma) per ml. The adherent cells
were washed with PBS and then cultured in Dulbecco’s modified Eagle’s medium
with 10% FCS, supplemented with 10 mg of LPS per ml. After 3 days of LPS-
stimulation, Vero cells in suspension were added at a density of 104 cells/ml, and
cultures were monitored for cytopathic changes during three passages. The pres-
ence of MV in cocultures was confirmed by reverse transcription (RT)-PCR as
described below.
Preparation of clodronate liposomes. Clodronate liposomes were prepared as
previously described (35). Briefly, liposomes composed of soy phosphatidylcho-
line, cholesterol and DL-a-tocopherol at 40 mg of soy phosphatidylcholine, 6 mg
of cholesterol, and 0.2 mg of tocopherol per ml (1:0.3:0.01 mol parts) were
prepared by freeze-thawing and filter extrusion. The dry lipid mixture was sol-
ubilized by addition of 1 ml of clodronate solution (Ostac; Boehringer Mann-
heim; 37.5 mg of sodium clodronate). The resulting multilamellar vesicles were
freeze-thawed in three cycles of liquid nitrogen and water at 40°C, followed by
repetitive (five times) filter extrusion through 400-nm-pore-size membranes
(Nuclepore; Sterico, Dietikon, Switzerland) using a Lipex extruder (Lipex Bi-
omembranes Inc., Vancouver, Canada). For the determination of clodronate
encapsulation efficiency, the preparations were trace labeled with 45CaCl2 (Am-
ersham Pharmacia Biotech, Du¨bendorf, Switzerland) and 1 mM CaCl2 as carrier.
Unencapsulated clodronate was removed in two steps by concentration to 4 to 5
ml with an Amicon ultrafiltration cell using a YM100 (100-kDa cutoff) mem-
brane followed by size exclusion chromatography on a Sephadex G25 column (30
by 2.5 cm; Pharmacia) with phosphate buffer (67 mM, pH 7.4) as the eluent. The
diluted liposomes collected after column elution were reconcentrated by ultra-
filtration to obtain a final volume of 3 to 4 ml containing 8 to 12 mg of clodronate/
ml. All preparations were sterile filtered through a 0.45-mm-pore-sized filter
(Gelman). Liposome size and homogeneity were routinely measured with a
Nicomp (Santa Barbara, Calif.) 370 laser light-scattering particle sizer. The
clodronate liposomes were used within 10 days after preparation.
Macrophage depletion in vivo. Depletion of splenic macrophages in 5- to
8-week-old mice was achieved by i.p. injection of 2 mg of clodronate liposomes
per animal. Mice injected with the same volume of empty liposomes were used
as a control. Three days later, mice were injected i.p. with 106 PFU of MV-Ed.
Mouse specimens, including spleen, liver, lung, and blood, were harvested at 3
days after virus administration for analyses of MV pathogenesis. Macrophage
depletion efficiency was monitored by cell-specific analysis of collected tissues
and fluorescence-activated cell sorter analysis of F4/80-positive cells in the pe-
ripheral blood samples.
For depletion of lung-associated macrophages, 1 mg of clodronate liposomes
per mouse was administered i.n. 3 days and 1 day before virus infection, and the
lung tissues and blood samples were collected 3 days after i.n. administration of
106 PFU of MV-Ed.
MV RNA quantification by real-time PCR analysis. Total RNA from mouse
organs was extracted as previously described (28). For RT, the minus-strand
primer 59-TTATAACAATGATGGAGGGTAGGC, hybridizing to the last 24
nucleotides of the N mRNA, was used. Real-time quantitative TaqMan PCR
based on the primer pair 59-GGGTACCATCCTAGCCCAAATT and 59-CGA
ATCAGCTGCCGTGTCT, amplifying 73 bases of the N mRNA, and the mo-
lecular beacon 59-FAM-CGCAAAGGCGGTTACGGCCC-DABCYL, where
6-carboxyfluorescein (FAM) serves as the reporter fluorochrome and 4-dimeth-
ylaminophenylazobenzoic acid (DABCYL) serves as the quencher, was per-
formed according to the protocol of the supplier (Perkin-Elmer, Applied Bio-
systems). Briefly, each 25-ml reaction mixture contained 2 ml of cDNA from the
RT reaction, 12.5 ml of TaqMan PCR Master Mix (Perkin-Elmer), a 240 nM
concentration of each primer, and 160 nM molecular beacon. One cycle of
denaturation (95°C for 10 min) was applied, followed by 45 cycles of amplifica-
tion (95°C for 15 s and 60°C for 1 min). PCR was carried out in a spectropho-
tometric thermal cycler (ABI PRISM 7700 Sequence Detection System; Perkin-
Elmer) that monitors changes in the fluorescence spectrum of molecular beacon
FAM in each reaction tube during the course of the reaction, resulting in a
real-time analysis.
For real-time PCR quantification, a standard curve was generated from trip-
licate samples of purified MV N RNA transcribed in vitro. Briefly, an MV N
gene-containing plasmid, p(1)MNPCAT (33), was linearized with StuI and tran-
scribed in vitro by using T7 RNA polymerase. After digestion of the DNA
template with RNase-free DNase I (Roche, Basel, Switzerland), the generated
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MV N RNA transcript was purified and analyzed on an agarose gel, followed by
determination of the concentration by spectrophotometry. The linear copy num-
ber range from 4 3 1010 to 4 3 103 copy equivalents per reaction (10-fold
dilutions) was taken for RT-PCR amplification and detection of corresponding
threshold cycles, which ranged from 14 to 31, corresponding to 4 3 1010 to 4 3
103 MV N RNA copy equivalents per RT-PCR, respectively. The determined
viral RNA load was expressed as MV N RNA copy number per 1 mg of total
RNA, and the calculation of MV N RNA copies per average cell was done by
considering that about 2 3 105 splenic cells contain approximately 1 mg total
RNA.
Histological, IHC, and ISH assays. Histological, immunohistochemistry (IHC)
and in situ hybridization (ISH) assays were done as described previously (27).
Briefly, mouse tissue specimens for IHC analysis were collected at the times
indicated, immersed in Hanks balanced salt solution, and snap frozen in liquid
nitrogen. Two- to three-micrometer-thick tissue sections were cut in a cryostat,
fixed with acetone, and stored at 270°C. Specimens for ISH were fixed in 4%
PBS-buffered formaldehyde, embedded in paraffin, and then cut at 2 mm.
For the staining of cell differentiation markers, the following primary rat
anti-mouse monoclonal antibodies were used: antibodies against CD45R/B220
(RA3-6B2; PharMingen), CD3 (KT3), CD4 (YTS 191), CD8 (YTS 169), F4/80
macrophages (A3-1) (American Type Culture Collection, Manassas, Va.),
splenic marginal metallophilic or marginal zone macrophages (MOMA1 or
ERTR9) (Biomedicals AG, Augst, Switzerland), follicular DC (4C11), and in-
terdigitating DC (NLDC145) (Biomedicals AG). CD11c was stained with a
primary monoclonal hamster antibody (N418). Detection of newly formed ger-
minal centers was done with anti-peanut agglutinin (anti-PNA) and polyclonal
rabbit anti-PNA antibodies. Primary antibodies were revealed by sequential
incubation with alkaline phosphatase-labeled species-specific secondary antibod-
ies (Jackson ImmunoResearch Labs, West Grove, Pa.). Alkaline phosphatase
was visualized using naphthol AS-BI (6-bromo-2-hydroxy-3-naphtholic acid-2-
methoxy anilide) phosphate and new fuchsin (Sigma) as a substrate, yielding a
red reaction product. Sections were counterstained with hemalum.
Detection of MV N mRNA in situ was performed with a digoxigenin-labeled
N RNA probe on prehybridized paraffin sections under appropriate conditions as
previously described (28). Hybridized probes were immunologically detected
using a digoxigenin-nucleic acid detection kit (Roche).
RESULTS
MV replication in PBMC. MV-infected F4/801 macro-
phages were detected after i.n. inoculation in several tissues of
Ifnarko-CD46Ge mice, raising the possibility that these cells
may disseminate MV infection (27). Previous studies revealed
that PBMC of these animals are MV positive (28) without
establishing which subtypes of circulating PBMC are infected.
To obtain this information, we analyzed MV H protein expres-
sion at the surface of B2201 B cells, CD41 T cells, CD81 T
cells, or F4/801 MM isolated from infected Ifnarko-CD46Ge
mice and from the parental CD46Ge animals. Double-labeling
flow cytometric analysis was performed 3 and 6 days after i.n.
or i.p. infection with MV-Ed.
Three days after i.n. infection, most Ifnarko-CD46Ge mice
(seven of nine animals) expressed the H protein on about 1.8%
of F4/801 cells (Table 1). H antigen was also detected in a
smaller fraction of B2201 B lymphocytes and CD41 T cells in
fewer animals. In contrast, H protein expression was not de-
tectable on CD81 T cells.
Ifnarko-CD46Ge mice were then injected i.p. with the same
amount of virus, and their PBMC were examined. As shown in
Table 1, at 3 days p.i. H protein was observed at an average of
3.2% on F4/801 cells, and at 0.8 to 1% on B2201 B cells or
CD41 T cells, in the majority of animals. In contrast, CD81 T
cells were weakly positive in only one of five mice. Thus, 3 days
after either i.n. or i.p. inoculation of Ifnarko-CD46Ge mice,
F4/801 MM were infected at levels that were about three times
higher than those for B2201 B cells or CD41 T cells; in con-
trast, infection of CD81 T cells was negligible.
MV infection of immune cells was also examined at 6 days
p.i. in other groups of mice inoculated i.n. or i.p. with MV-Ed.
At this later time the expression of H antigen on both MM and
lymphatic cells was still positive, and preferential replication in
F4/801 cells was confirmed (data not shown).
In addition, we investigated if the virus was recovered from
adherent or nonadherent PBMC subsets isolated from i.p. in-
fected Ifnarko-CD46Ge mice. Virus recovery was positive, after
stimulation with LPS as a mitogen and cocultivation with Vero
cells, in three of seven instances when adherent cells were used
and in one case for the nonadherent cells.
We then asked if preferential MV replication in MM re-
quires interferon receptor knockout as well as CD46 positivity.
To this end, we infected the parental mouse line, CD46Ge,
expressing human CD46 with human-like tissue specificity and
having an intact interferon type I receptor, with the same virus.
As shown in Table 1, at 3 days p.i. MV H expression was
observed at about 1.4% of F4/801 cells of most i.p. infected
mice and again at two- to three-times lower levels in lymphoid
B2201 B or CD41 T cells. CD81 T cells were negative. When
PBMC of CD46Ge mice were analyzed at 6 days p.i., no pos-
itive cells were detected (data not shown). As a control, wild-
type C57BL/6 mice were also infected with the same inoculum.
No positive H protein staining was detected in the immune
cells of these animals. We thus conclude that efficient MV
infection of F4/801 MM depends on human CD46 expression
in these cells.
Previously, we found that lymphocytes of CD46Ge mice
express CD46 levels comparable to those of human lympho-
cytes (28), but we did not compare CD46 expression in differ-
ent PBMC populations. We therefore performed this analysis
and determined that B2201 cells had the highest CD46 expres-
sion levels, followed by F4/801, CD41, and CD81 cells (mean
fluorescence of 30, 24, 11, and 5, respectively, data not shown).
We conclude that there is no direct correlation between the
level of human CD46 expression and the efficiency of MV in-
fection.
Different inoculation routes lead to efficient infection of
F4/801 macrophages. As shown in Table 1, levels of MV in-
fection in PBMC, including MM, are highest after i.p. inocu-
lation. Since data on systemic MV replication in Ifnarko-
CD46Ge mice were previously obtained only after i.n.
TABLE 1. MV H protein expression in peripheral blood cells of
Ifnarko-CD46Ge and CD46Ge mice inoculated i.n.
or i.p. with MV-Ed
Cell type
No. of MV H protein-positive mice/totala
Ifnarko-CD46Ge CD46Ge
(i.p. inoculated)i.n. inoculated i.p. inoculated
F4/801 7/9 (1.81 6 1.02) 4/5 (3.24 6 1.86) 6/7 (1.37 6 0.63)
B2201 6/9 (0.58 6 0.48) 3/5 (0.78 6 0.44) 4/7 (0.67 6 0.29)
CD41 4/9 (0.62 6 0.46) 5/5 (0.99 6 0.80) 6/7 (0.54 6 0.28)
CD81 0/9 1/5 (0.67) 0/7
a In parentheses is the percentage of positive cells (mean 6 standard deviation
after background correction); only positive animals were considered. On average
1,300 F4/801 cells, 7,600 B2201 cells, 4,100 CD41 T cells, and 2,000 CD81 T
cells were counted. Fluorescence-activated cell sorter analysis of CD46 expres-
sion on cells of eight mice revealed a mean fluorescence of 24 for F4/801 cells,
30 for B2201 cells, 11 for CD41 T cells, 5 for CD81 T cells, and 0.1 for
erythrocytes.
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inoculation, we examined lymphatic and other organs of these
mice for MV replication at 3, 6 or 12 days after i.p. infection.
The most prominent virus-specific pathology was observed at 3
days p.i. in lymphatic tissues; multinucleated giant cells ex-
pressing MV N mRNA were detected in the spleen (Fig. 1A
and B) and in the lymph nodes (data not shown). In the spleen,
sites of virus replication were detected in the red pulp and in
the marginal zone (Fig. 1A) and sporadically in the white pulp.
The combination of MV ISH and cell-specific IHC on consec-
utive tissue sections was then utilized to identify infected
cells. Macrophage (F4/80, MOMA1, and ERTR9), T-cell (CD3,
CD4, and CD8), B-cell (B220), and DC (NLDC145 and CD11c)
cell markers were analyzed. Colocalization of positive signals
was found mainly in F4/801 macrophages (Fig. 1B and C),
occasionally in MOMA11 cells, and only in a few CD41 T cells
or DC (data not shown), confirming the placement of most in-
fected cells in the macrophage lineage. By 6 days p.i., the rep-
licating virus was detected in other systemic organs, including
lungs (Fig. 1D) and liver, kidney, heart, and pancreas (data not
shown), and co-localization of replicating virus in the lungs was
again observed in F4/801 cells (Fig. 1D and E). At 14 days p.i.,
the tissue pathology was moderate if detectable. Nevertheless,
single MV replicating cells were observed in brain, approxi-
mately 10% of which were macrophages (data not shown).
We then asked if i.c. inoculation of mice with MV-Ed would
result in macrophage infection. Indeed, replicating virus was
observed during the first week p.i. not only in single F4/801
cells (Fig. 2A and B) but also in a multinucleated giant F4/801
cells localized in the brain ventricles (Fig. 2C and D) or pa-
renchyma (intravascular or perivascular), indicating that these
circulating cells are susceptible to virus-induced fusion. Thus,
F4/801 cells are targets for MV not only after i.n. but also after
i.p. or i.c. virus administration.
DC disseminate MV infection in macrophage-depleted mice.
Having shown that macrophages are associated with MV dis-
semination in Ifnarko-CD46Ge mice, we examined whether
these cells are necessary for efficient propagation of MV in-
fection in these animals. Clodronate liposomes administered
by different routes can specifically deplete macrophages in
different organs (41). In order to deplete splenic macrophages,
Ifnarko-CD46Ge mice were injected i.p. with clodronate lipo-
somes. Figure 3 documents by specific IHC the extent of de-
pletion of three splenic macrophage subpopulations: the red
pulp F4/801 (Fig. 3D), metallophilic marginal zone MOMA11
FIG. 1. MV-Ed infects F4/801 macrophages in spleen and lung. (A to C) Sections of the spleen 3 days after i.p. infection. (A) Low magnification
showing MV N RNA-positive cells in the red pulp (rp). (B and C) Consecutive sections showing colocalization of MV N RNA (B) with the MM
marker F4/80 (C) in syncytia. (D and E) Consecutive lung sections 6 days after i.p. infection showing MV-specific RNA signals (D) colocalizing
with F4/80-positive cells (E). wp, white pulp (darker area). Magnifications, 387.5 (A) and 3875 (B to E).
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(Fig. 3E), and marginal zone ERTR91 (Fig. 3F) cells. In con-
trast, control empty-liposome-treated mice showed normal
densities and distributions of all macrophages (Fig. 3A, B, and
C). In addition, CD11c1 or NLDC1451 DC, 4C111 follicular
DC, and B or T cells were not affected (data not shown).
Furthermore, as monitored by the flow cytometric assay, in 10
of 12 mice the clodronate liposomes were effective in elimi-
nating 95% of circulating blood F4/801 cells, whereas in the
two remaining animals approximately 70% depletion was ob-
served (data not shown). Macrophage depletion was observed
in livers from clodronate liposome-treated mice but not in
their lungs (data not shown). Thus, i.p. injection of Ifnarko-
CD46Ge mice with clodronate liposomes resulted in selective
depletion of splenic and liver macrophage subpopulations
without any effect on other cell populations, as previously re-
ported for wild-type mice (35).
Three days after clodronate liposomes treatment, the mice
were infected with MV-Ed i.p., and at 3 days p.i. blood cells
and tissues, including spleen, liver, and lung, were collected
and analyzed by MV-specific ISH and cell-specific IHC. MV
pathogenesis characterized by viral replication in the white
pulp (Fig. 4A), syncytium formation, and apoptosis (pycnotic
nuclei in the syncytia shown in Fig. 4B) was observed. MV
infection of remaining F4/801 cells in the red pulp was ob-
served in only a few locations. IHC of tissue sections detected
reticular CD11c1 (Fig. 4B) and interdigitating NLDC1451
FIG. 2. MV replication in the brain 3 days after i.c. inoculation of mice. Colocalization of F4/80-positive cells (A and C) and MV N mRNA
(B and D) within single cells (A and B) and a syncytium (C and D) in the brain ventricle is shown. Magnification, 3875.
FIG. 3. Depletion of splenic macrophage subpopulations after i.p. treatment with clodronate liposomes. Splenic tissues obtained from mice
injected with empty liposomes (A to C) or with clodronate liposomes (D to F) are shown. Six days after treatment, sections were IHC stained for
red pulp F4/801 macrophages (A and D), marginal zone metallophilic MOMA11 macrophages (B and E), and marginal zone ERTR91
macrophages (C and F). Magnification, 377.5.
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(Fig. 4C) DC as the most common cells within syncytia located
in the margin of the T- and B-cell areas and in the newly
formed germinal center areas of the white pulp. Double-pos-
itive CD31 CD41 T cells (Fig. 4D) were detected within those
NLDC1451 CD11c1 syncytia less frequently, and CD31 CD81
T cells or B2001 B cells were detected only occasionally (data
not shown).
In addition, the splenic tissue organization revealed very
prominent induction of PNA-positive germinal center forma-
tion within the majority of splenic follicules (Fig. 4E). More-
over, we detected increased populations of 4C111 follicular
DC, many of which were also fused and colocalized with
NLDC1451 CD11c1 syncytia within B-cell areas (data not
shown). These data suggest that in spleens of macrophage-
depleted mice, the main MV replicating cells are NLDC1451
CD11c1 DC located in the white pulp.
To determine if macrophage depletion influenced the viral
load in other PBMC, MV H protein expression was analyzed in
10 clodronate liposome-treated Ifnarko-CD46Ge mice in which
95% of circulating blood F4/801 cells were depleted. Four of
these mice expressed H protein on B2201 cells (mean, 0.46%),
and two mice expressed H protein on CD41 cells (mean,
0.66%). H protein was not detectable on the remaining F4/801
cells; in only two mice with a 70% depletion was H protein
detected on these cells. A control mouse treated with empty
liposomes had slightly higher expression levels, similar to those
of the animals presented in Table 1, second column.
To monitor the effects of macrophage depletion on viral
load, total RNA was isolated at 3 days p.i. from the spleens of
the same clodronate liposome-treated and control mice. MV N
gene transcripts were quantified by RT–real-time PCR by com-
parison to a standard curve. As shown in Table 2, about 10
times more MV transcripts were detected in total spleen RNA
of clodronate liposome-treated mice than in spleens of control
mice (2 3 107 versus 2 3 106 molecules/mg of total RNA,
corresponding to about 100 versus 10 copies of MV N RNA
per cell, respectively). At a later time point (14 days p.i.), the
virus load declined in both clodronate liposome-treated and
control mice (Table 2). Thus, even if slightly fewer circulating
MV-infected PBMC were detected in clodronate liposome-
treated mice, MV infection propagated more efficiently in the
spleens of these mice than in control mice.
Having observed that the depletion of splenic macrophages
resulted in higher levels of DC infection in the spleen, we
then sought to verify the effects of the depletion of lung
macrophages on MV propagation. To attempt depleting lung
macrophages, we treated seven mice i.n. with clodronate lipo-
somes. IHC analysis of lungs revealed nonhomogenous deple-
tion of F4/801 or MOMA11 macrophages; areas of lung lobes
proximal to the bronchi were more efficiently depleted (Fig.
4F; arrows point to apoptotic cells) than the more distal areas
(Fig. 4J and K). However, at 3 days after i.n. MV administra-
tion, in such macrophage-depleted lungs a marked infiltration
of CD11c1 cells within and below the airway epithelium, and
within the alveolar septal walls was found (Fig. 4G). MV was
detected in numerous CD11c-positive syncytia (Fig. 4H), many
of which were also positive for the NLDC145 cell marker (Fig.
4I). In addition, a weak B-cell infiltration was noted, but there
was no effect on T-cell populations (data not shown). Never-
theless, in the same lung sections many infected F4/801 (Fig.
4J) and MOMA11 (Fig. 4K) syncytia were also detected, in-
dicating a heterogenous cellular tropism of the virus. The lung
pathology after control i.n. administration of empty liposomes
followed by MV infection is characterized by high levels of
virus replication in F4/801 syncytia without significant effect on
DC, as described for nontreated mouse lungs (27). These ob-
servations suggest that in vivo depletion of endogenous lung
tissue macrophages resulted in strong local infiltration of DC
and in virus infection of both infiltrating NLDC1451 and
CD11c1 DC and macrophages.
DISCUSSION
We report here that MV replicates in PBMC, including both
MM and lymphoid B or T cells, in two mouse strains express-
ing CD46 with human-like tissue specificity and efficiency. In
particular, MV replication is most prominent in F4/801 cells
shortly after inoculation by three different routes. Thus, it
seems plausible that MM serve as early vectors for MV dis-
semination. When MM were depleted by clodronate liposome
treatment, numerous infected DC were detected in the spleen
and lungs, and the splenic virus load was increased. Thus, MM
support virus replication early after host infection, but they
also contribute to protecting other immune cells from infec-
tion.
Circulating MM serve as vectors for MV dissemination.
Based on the observation that MV-positive F4/801 cells were
often detected in infected organs after i.n. inoculation of If-
narko-CD46Ge mice, MM were considered as candidate vec-
tors for MV dissemination (27). To further investigate this
possibility, we determined if F4/801 cells could be detected
early after infection of Ifnarko-CD46Ge mice not only by the
i.n. route but also by the i.p. and i.c. routes. Indeed, 3 days after
i.n. inoculation of these mice, about 1.8% of the circulating
MM were infected. The percentage of infected MM was above
3% after i.p. infection and was three to four times higher than
that of infected B- and CD4-positive T cells. These results are
consistent with efficient virus uptake and replication by mac-
rophages, which are numerous in the peritoneum. The third
inoculation route was i.c., resulting again in efficient infection
of F4/801 cells. Thus, macrophages are consistently and rap-
idly infected after MV inoculation. This is the case not only for
Ifnarko-CD46Ge mice but also for the parental line CD46Ge,
where about 1.4% of circulating F4/801 macrophages were
infected shortly after i.p. inoculation. However, these animals
were able to rapidly clear the infection, while in Ifnarko-
CD46Ge mice MV infection disseminated systemically.
TABLE 2. MV N RNA in macrophage-depleted
versus intact mouse spleensa
Treatment Daysp.i.
No. of
mice
Mean (SD) MV N RNA
copies/mg of total RNA
Clodronate liposomes 3 10 2 3 107 (5.4 3 106)
14 6 3 3 106 (5.1 3 105)
Empty liposomes 3 5 2.7 3 106 (8.4 3 105)
14 2 1 3 106 (both mice)
a Mice were injected with clodronate liposomes i.p. and 3 days later were
infected with MV-Ed i.p. At 3 or 14 days p.i. spleens were collected, total RNA
was isolated, and the viral RNA was quantified as described in Materials and
Methods.
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Quantitative data regarding the percentages of different sub-
species of PBMC infected during acute measles are not avail-
able, but 0.01 to 2% of total PBMC were productively MV
infected 2 to 3 days after onset of the rash in adults with severe
acute measles (10). Moreover, data on the percentage of MV-
infected cells after i.c. inoculation of neonatal CD46-express-
ing mice, collection of their spleens, and analysis of separated
splenocytes have been obtained (31). In different populations
of splenocytes, including CD8-positive cells, 0.09 to 1.0% MV-
infected cells were observed. Thus, even at the peak of severe
acute measles in humans and of experimental infection of
mice, only a small fraction of immune cells appear to produc-
tively replicate MV.
Can infections of CD46-expressing mice be expected to
faithfully mimic acute MV infection in humans? More than
one receptor is involved in MV entry in human cells (39), and
late events in MV replication are restricted in certain mouse
cells (42). Therefore, it may not be realistic to expect faithful
reproduction of all aspects of human MV infections in trans-
genic mice. Nevertheless, the data presented here do suggest
that MV infection of PBMC in CD46-expressing mice may
mimic several aspects of PBMC infection in acute measles in
humans.
MM depletion results in more efficient DC infection. To
further characterize their role as host cells in MV infections of
mice, macrophages were selectively depleted by treatment with
clodronate liposomes (41), a method previously used to study
other viral infections (16, 35). After i.p. administration of clo-
dronate liposomes, we observed in Ifnarko-CD46Ge mice the
depletion of circulating F4/801 MM and of three different
splenic macrophage populations: red pulp F4/801, metallo-
philic marginal zone MOMA11, and marginal zone ERTR91
macrophages. The other splenic cells, including DC and non-
phagocytic lymphoid B or T cells, were not affected, consistent
with data obtained for other mouse strains showing that apart
from macrophages, only their direct monocytic precursors are
depleted by clodronate liposomes treatment (19, 35).
In such macrophage-depleted mice infected i.p. with MV,
virus replication in splenic tissues differed in microanatomical
location and infected cell types compared to that in control
mice expressing normal macrophage levels. In control mice,
MV replication was located in the red pulp and the marginal
zone, primarily in fused F4/801 or MOMA11 macrophages.
CD31 CD41 T cells were rarely detected within the syncytia,
and DC were detected only in a few syncytia located in the
white pulp. Previously, in mice infected i.n. with MV a low
level of infected thymic NLDC1451 CD11c1 DC was observed
during the late phase of infection (27). In contrast, in macro-
phage-depleted mice MV replicated mainly in the white pulp,
and numerous fused NLDC1451 CD11c1 DC were observed.
Moreover, at the interface between T- and B-cell areas, CD41
CD31 T cells were involved in syncytia that were also positive
for NLDC1451 CD11c1 cells. Finally, in B-cell areas and in
newly formed germinal centers, B2201 cells or 4C111 follicu-
lar DC were involved in syncytia. These data from spleens and
similar observations for lungs strongly suggest that infected DC
may fuse to local neighboring immune cells. Thus, in untreated
mice macrophages may protect DC from MV infection.
It is noted that in clodronate liposome-treated mice the
splenic viral load increased by about 10 times at 3 days p.i.,
which is a small factor compared to increases observed in
macrophage-depleted mice infected with two other macro-
phage-tropic viruses, namely, murine cytomegalovirus and lym-
phocytic choriomeningitis virus (16, 35). This increase in viral
load is consistent with the observation that the interaction of
MV-infected DC with T cells in vitro induces syncytium for-
mation where MV undergoes more efficient replication than in
MV-infected monocytes (11). It is conceivable that DC infec-
tion might have other effects on MV pathogenesis, especially
on the induction of host immunity. In particular, the induction
of germinal center formation is rapid and occurs already at 3
days p.i., much earlier than by day 12 as after other viral
infections. Germinal centers are required to maintain high-
level production of neutralizing antibodies (2).
Innate immunity and dissemination of MV infection. It is
interesting that prominent infiltration with and activation of
immune cells, including those with DC-like morphology, was
also described after in vivo depletion of alveolar macrophages
of wild-type mice (40) or in pulmonary tissues of rats (18)
treated with a nonviral antigen. To explain these findings, it
was suggested that the uptake of pathogens primarily by mac-
rophages may contribute to a fine-tuned balance that must
provide not only protection from the pathogen but also limi-
tation of excessive tissue destruction which can be induced by
a strong host immune reaction.
This might also be valid for MV infections. The innate im-
mune system consisting of endogenous macrophages and
freshly recruited monocytes may be responsible for the early
capture and dissemination of MV in Ifnarko-CD46Ge mice.
After experimental depletion of endogenous macrophages, DC
residing in local tissues (3) may more readily capture MV and
be activated. Those DC that have internalized and are repli-
cating the virus, or that have absorbed it on their surface (12),
may then leave the local tissues and migrate into the white pulp
of the spleen where they stimulate the effector T and B cells of
the adaptive immune system. By doing so, DC may also dis-
seminate the infection throughout the host tissues and subse-
quently seed neighboring permissive cells, similar to the case
for human immunodeficiency virus (6, 12).
It is important to determine the consequences for the im-
mune response of the switch of MV dissemination from MM to
DC. It is conceivable that enhanced DC infection may result in
immune suppression due to the apoptosis of DC and of the
contacted T cells (11). In an opposite scenario, enhanced pre-
sentation of MV antigens by DC may lead to more prominent
induction of both antiviral neutralizing B-cell immunity and
T-cell-mediated immunity (22, 23). The rapid induction of
germinal centers appears to be consistent with this scenario. If
antiviral immunity is stronger after enhanced DC infection,
recombinant MV targeting DC may be more efficient vaccines.
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